Earnings ·
Biodesix reports Q3 revenue of $24.0M and revises full-year guidance to $101M-$103M
BDSXBiodesix Inc
Biodesix reported third-quarter 2026 total revenue of $24.0 million, a 10% increase year over year, driven by a 16% rise in Diagnostic Testing revenue and a 24% increase in test volumes to 19,400. The company maintained an 81% gross margin but reported a net loss of $8.0 million and an Adjusted EBITDA loss of $3.9 million. Management cited execution challenges, including fewer sales representatives than planned and seasonality delays, as primary drivers for growth below expectations. Consequently, Biodesix revised its full-year 2026 revenue guidance to a range of $101 million to $103 million. The company also highlighted strategic progress in lung diagnostics, including new partnerships and product developments.